IMRX Projected Dividend Yield

Cl A/Immuneering Corp ( NASDAQ : IMRX )

Immuneering is focused on improving patient outcomes by improving a pipeline of oncology and neuroscience product candidates developed using Co.'s translational bioinformatics platform. Co.'s development programs in oncology is focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and mTOR pathways. Co.'s primary product candidate, IMM-1-104, is designed to be a selective dual-mitogen-activated protein kinase kinase inhibitor that further disrupts kinase suppressor of RAS 1 and 2 to modulate the signaling dynamics of the MAPK pathway. In addition to IMM-1-104, Co. has six other oncology programs in the discovery stage.

20 YEAR PERFORMANCE RESULTS